July 23, 2024
This potential merger has traders in a frenzy ?

This potential merger has traders in a frenzy ?

  

Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street!

PRST – Up over 40% in pre-market as this AI name finally receives attention from traders

XPEV – Up 11% in pre-market after unveiling its next-generation integrated technology architecture SEPA 2.0 over the weekend, which includes autonomous driving

BLBX – Trades over 280% higher in pre-market after announcing LOI to merge with EV supplier

*A Message on Behalf of Market News Dispatch

BioSig Technologies (Nasdaq: BSGM)

Today, we want to bring your attention to a small medical device maker that has cleared FDA approval and is rapidly starting to ramp up sales.

BSGM average analyst rating pegs the stock price over 300% higher than current levels

BSGM technical indicators are super-strong right now

From the chart below, you can see that daily indicators have been very good at signaling future price movements. Right now is a crucial level to watch.

SeekingAlpha has a pristine “A rating” when it comes to its momentum metrics. I wonder what could be around the corner for the stock price?!

Check out this detailed report on BSGM and make sure you keep it on your trading radar this week!

*Sponsored by Lifewater Media. Please see disclosures below.

PRST – Up over 40% in pre-market as this AI name finally receives attention from trade

Presto Automation (PRST) is gapping up over 40% this morning on no news. PRST saw no action last week as other AI names ran, perhaps because the ticker symbol doesn’t end in AI as silly as that may seem. However, perhaps some traders realized this over the weekend and traders have flocked to PRST in the pre-market.

On the 5th of April PRST announced they would host a summit on May 5th for technology companies driving the adoption of enterprise grade AI. Previously the company announced a collaboration with OpenAI’s Chat GPT API to expand the Presto Voice feature set.

The $2-$1.95 area was resistance in the pre-market and has since acted as support, so that should be an important level to watch.

Above it, the first major target was the early pre-market high of $2.25. Beyond that targets to the upside are at $2.50, $3, $3.50 and $4.

Below $1.95, there is potential support at $1.80, $1.70 and then a gap to fill at $1.39.

XPEV – Up 11% in pre-market after unveiling its next-generation integrated technology architecture SEPA 2.0 over the weekend, which includes autonomous driving

XPeng (XPEV), a leading Chinese smart electric vehicle maker, unveiled its next-generation end-to-end integrated technology architecture SEPA 2.0, which sets the foundation for future production models.

SEPA 2.0 (Smart Electric Platform Architecture) brings a series of more advanced architectural solutions, from XPENG’s in-house development autonomous driving software to vehicle engineering. It will shorten future models’ R&D cycle by 20%, significantly optimizing R&D efficiency.

The company claims it also optimizes overall vehicle R&D costs by 50%, shortens software iteration cycles by 30% and increases OTA update speed by 300%.

The ADR is up over 11% after the presentation and press release.

$11.02 has been a support level in pre-market after the initial gap higher this morning.

Above it, targets to the upside are $11.10, $11.15 and the pre-market high at $11.18. Beyond that targets are $11.50, $12, $12.36 and $12.88.

Below $11.02, there is potential support at $10.88, $10.80, $10.40, $10 and a gap to fill at $9.92.

BLBX – Trades over 280% higher in pre-market after announcing LOI to merge with EV supplier

Blackboxstocks announced this morning that it had signed a Letter of Intent to merge with Evtec Group, a leading supplier for luxury brands in the electric vehicle (EV) market with projected revenue of $132 million for year ending March $2024.

Evtec is a supplier of proprietary parts for leading Luxury, Performance, and Electric Vehicle “EV” brands including Jaguar Land Rover, Aston Martin, and Ford, among many others.

Although this is not a definitive merger agreement but a LOI at this stage, Blackbox Stockholders are expected to retain 8.34% of the common shares of the combined company’s common stock post-merger.

BLBX stock traded over 280% higher on the news.

$9.70 has acted as a support area so far in the pre-market and should be an important pivot level today.

Above it, targets to the upside are $10.85, $11.20, $11.60 and then the pre-market high of $12.47. Beyond that, targets to the upside are $14 and then $16.

Below $9.70, there is potential support at $9.10, $8.60, with $7.20 and $6.10 below that. The stock closed at $2.64 yesterday.

8:30am Empire State MFG index

10:00am Housing Market index

12:00pm Fed Speaker Thomas Barkin

4:00pm Treasury International Capital

Earnings for Today (After Market)

CFB, DBGI, ELS, FBK, INVO, JBHT, MARK, PNFP, SFBS, XWEL

FFIE Faraday Future’s First Production FF 91 Vehicle Comes off the line at its FF ieFactory California, and Kicks off the Final Launch & Delivery Campaign

MNTS Momentus Launches Vigoride-6 Orbital Service Vehicle on SpaceX Transporter-7 Mission

GILD Veklury(R) (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations

RXDX MRK Merck Will Buy Prometheus Biosciences for $200 Per Share * Agreed price a 75% premium to biotech company’s Friday close * Pharma giant looking to grow its presence in immunology BBG

TSLA Tesla China initiates recruitment for Megapack manufacturing plant in Shanghai

MRK Merck’s KEYTRUDA(R) (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer

MRNA: Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA

AZN IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

BARCLAYS to cut more than 100 investment banking roles – SKY

AFMD Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023

GOOG Samsung is considering removing google as the default search engine on its phones. It is looking to make Microsoft’s Bing the default search engine per NYT

LNZA: LanzaTech plans announced for Wales’ first Sustainable Aviation Fuel production in Port Talbot

BIDU Baidu Apollo Releases Major Product Updates to Help Manufacturers Build Smarter Cars for Tomorrow

AAPL Apple BKC in Mumbai opens for customers this Tuesday

ARGX argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

ABBV AbbVie Announces European Commission Approval of RINVOQ(R) (upadacitinib) for the Treatment of Moderately to Severely Active Crohn’s Disease

MVIR IGMS Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

MGA Magna Adds to Its Complete Vehicle Manufacturing Lineup With an All-New Electric Vehicle From INEOS Automotive

AI ChatGPT and advanced AI face new regulatory push in Europe – WSJ

HOPE Hope Bancorp Announces Notification to Holders of 2.00% Convertible Senior Notes of Their Contractual Put Right

YY JOYY Inc. Announces Repurchase Right Notification for 0.750% Convertible Senior Notes due 2025

HIVE HIVE Blockchain Provides March 2023 Production Update with over 3 Exahash of Production

TPC Lunda Construction Awarded $62 Million I-494 Bridge Repair Project

UNTY: Unity Bancorp Reports Quarterly Earnings of $10.3 Million

GOGN GoGreen Investments Corporation Confirms Funding and Extension of Deadline to Complete Initial Business Combination

PCVX: Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

SPIR: Three Spire Global Satellites Successfully Launch on SpaceX Transporter-7 Mission

NNVC: NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate

BMY: Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma

AQN AEP Algonquin Power & Utilities Corp. and American Electric Power Mutually Agree to Terminate Kentucky Power Transaction

MITQ: Moving iMage Technologies Announces Projects for Three Colleges and Universities

GRTS: Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

TNXP: Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival

To Your Success!

Questions or concerns about our products? Email [email protected](C) Copyright 2022, RagingBull – Refund Policy – Privacy Policy – Terms & Conditions

*PAID ADVERTISEMENT. RagingBull has been paid fourteen thousand dollars by ach bank transfer by Lifewater Media for advertising BioSig Technologies from a period beginning on April 17 , 2023 through April 18 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in BioSig Technologies. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of BioSig Technologies, increased trading volume, and possibly an increased share price of the BioSig Technologies securities, which may or may not be temporary and decrease once the marketing arrangement has ended.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www. sec. gov/ edgar/ searchedgar/companysearch

WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

 

Source

Leave a Reply

Your email address will not be published. Required fields are marked *